Shots: Halozyme to receive $25M upfront plus $160 to $165M/target milestones payments based on development, regulatory & sales in addition to royalties. Roche to get rights for ENHANZE Technology for exclusive development of clinical stage candidates for therapy areas Roche also has an option to add two additional targets within a span of four years, […]Read More
